

Table E3. Mean LCLA of participants in RENEW at baseline and weeks 24 and 32

	Placebo (n = 36)		Opicinumab (n = 33)	
	Affected Eye	Fellow Eye	Affected Eye	Fellow Eye
Mean (SD) LCLA 1.25% Sloan letter chart, Letters				
Baseline ^a	3.5 (6.9)	17.9 (10.4)	5.7 (10.6)	22.3 (12.1)
Week 24 ^b	11.3 (11.8)	22.5 (9.4)	10.8 (11.0)	22.8 (11.6)
Week 32 ^b	12.6 (12.3)	23.1 (10.2)	12.8 (11.8)	22.5 (10.7)
Mean (SD) LCLA 2.5% Sloan letter chart, Letters				
Baseline ^a	6.8 (12.5)	28.6 (12.3)	12.5 (14.4)	31.9 (11.5)
Week 24 ^b	19.8 (12.8)	32.8 (8.1)	21.2 (13.8)	32.8 (12.1)
Week 32 ^b	21.6 (13.7)	33.2 (8.9)	22.3 (13.8)	32.0 (11.3)

LCLA, low-contrast letter acuity

^aOpicinumab, n = 31.^bOpicinumab, n = 32.